Switch theme
Sign up to access all valuation multiples
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
2020
3
LTM Revenue n/a
LTM EBITDA n/a
-$4.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PMGC Holdings has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, PMGC Holdings achieved revenue of n/a and an EBITDA of -$3.3M.
PMGC Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PMGC Holdings valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.7M | n/a | XXX | XXX | XXX |
| Gross Profit | $0.4M | $1.1M | XXX | XXX | XXX |
| Gross Margin | 26% | Infinity% | XXX | XXX | XXX |
| EBITDA | -$4.3M | -$3.3M | XXX | XXX | XXX |
| EBITDA Margin | -249% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$1.8M | -$4.3M | XXX | XXX | XXX |
| Net Margin | -105% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PMGC Holdings's stock price is $3.
PMGC Holdings has current market cap of $2.2M, and EV of -$4.1M.
See PMGC Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$4.1M | $2.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PMGC Holdings has market cap of $2.2M and EV of -$4.1M.
PMGC Holdings's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate PMGC Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PMGC Holdings and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$4.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.2x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPMGC Holdings's NTM/LTM revenue growth is n/a
PMGC Holdings's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.
Over next 12 months, PMGC Holdings's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PMGC Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PMGC Holdings and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PMGC Holdings acquired XXX companies to date.
Last acquisition by PMGC Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . PMGC Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PMGC Holdings founded? | PMGC Holdings was founded in 2020. |
| Where is PMGC Holdings headquartered? | PMGC Holdings is headquartered in United States of America. |
| How many employees does PMGC Holdings have? | As of today, PMGC Holdings has 3 employees. |
| Who is the CEO of PMGC Holdings? | PMGC Holdings's CEO is Mr. Graydon Bensler. |
| Is PMGC Holdings publicy listed? | Yes, PMGC Holdings is a public company listed on NAS. |
| What is the stock symbol of PMGC Holdings? | PMGC Holdings trades under ELAB ticker. |
| When did PMGC Holdings go public? | PMGC Holdings went public in 2023. |
| Who are competitors of PMGC Holdings? | Similar companies to PMGC Holdings include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of PMGC Holdings? | PMGC Holdings's current market cap is $2.2M |
| Is PMGC Holdings profitable? | Yes, PMGC Holdings is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
